Efruxifermin

Phase 3Protein / enzyme

Efruxifermin is a protein / enzyme that works as a FGF21 Fc Fusion.[2] It is being investigated across 1 indication, with its most advanced program in Phase 3.[1]

Efruxifermin is one of 13 fusion protein programs targeting Alcoholic Fatty Liver Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseActive, not recruiting

Alcoholic Fatty Liver DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Alcoholic Fatty Liver Disease

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

1 2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 3

Micardis

Boehringer Ingelheim

Approved

1 4

Prolia

Fosamax

Tricor

2 7

Efruxifermin

Akero Therapeutics

Phase 3

1 8

Niacor

AbbVie

Preclinical

1 9

Trulicity

Eli Lilly

Preclinical

1 10

Invokana

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 3Recruiting

NASH - Nonalcoholic Steatohepatitis

NCT06528314

Q1 2033

Phase 3Recruiting

Non-Alcoholic Steatohepatitis

NCT06215716

Clinical

Trials by Indication[1]

Hepatitis1 trial

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Completed· Akero Therapeutics logo

Akero Therapeutics·Phase 2·NCT04767529·128 enrolled

Alcoholic Fatty Liver Disease1 trial

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Active, not recruiting· Akero Therapeutics logo

Akero Therapeutics·Phase 3·NCT06161571·700 enrolled

Non-Alcoholic Steatohepatitis1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Recruiting· Akero Therapeutics logo

Akero Therapeutics·Phase 3·NCT06215716·1,650 enrolled

NASH - Nonalcoholic Steatohepatitis1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Recruiting· Akero Therapeutics logo

Akero Therapeutics·Phase 3·NCT06528314·2,150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Efruxifermin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Efruxifermin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Efruxifermin. EMBL-EBI & Wellcome Sanger Institute.
[4]
PubMed — 1 publication indexed for Efruxifermin. U.S. National Library of Medicine.
[5]
SEC EDGAR — Akero Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: FGF21 Fc Fusion[2]
Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Akero Therapeutics

Key Publications[4]

Efruxifermin in NASH: HARMONY Phase 2b Results

Lancet Gastroenterol HepatolOct 5, 2023DOI: 10.1016/S2468-1253(23)00272-2

Efruxifermin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Q1 2033

Trials by Indication[1]

Hepatitis1 trial

Alcoholic Fatty Liver Disease1 trial

Non-Alcoholic Steatohepatitis1 trial

NASH - Nonalcoholic Steatohepatitis1 trial

References

Drug Info

Quick Facts

Key Publications[4]

Related News